Merck (NYSE:MRK) reached a historic milestone in oncology today as the FDA approved KEYTRUDA (pembrolizumab) and its new subcutaneous twin, KEYTRUDA QLEX, for the treatment of platinum-resistant ovarian cancer.
Agilent Technologies (NYSE:A) announced today that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx as the first and only companion diagnostic to identify first-line patients with epithelial ovarian cancer (EOC) eligible for Merck’s blockbuster immunotherapy, KEYTRUDA.
Tenet Healthcare (NYSE:THC) posted a sharp rise in fourth-quarter profitability, fueled by a surge in high-acuity surgical procedures and the strategic streamlining of its hospital portfolio.
Avantor (NYSE:AVTR) is betting on a structural overhaul to break a cycle of underperformance, unveiling its "Revival" transformation program alongside fourth-quarter results that showed persistent revenue pressure.
Humana (NYSE:HUM) issued a sobering outlook for 2026, projecting that a significant drop in government bonus payments will weigh on its bottom line even as the insurer sees a massive rebound in customer acquisition.
Madrigal Pharmaceuticals (NASDAQ:MDGL) is doubling down on its dominance of the liver-disease market, announcing an expansive partnership with Ribo to develop next-generation gene-silencing therapies.
IRADIMED (NASDAQ:IRMD), a leader in MRI-compatible medical devices, reported record financial results for the fourth quarter and full year ended December 31, 2025.
Quest Diagnostics (NYSE:DGX) delivered a robust fourth-quarter beat on Tuesday, February 10, 2026, as the company’s pivot toward high-growth hospital partnerships and consumer wellness testing pushed annual revenue past the $11 billion milestone.
Incyte (NASDAQ:INCY) delivered a robust finish to 2025 on Tuesday, February 10, 2026, marking its first year crossing the $5 billion revenue threshold.
InMode (NASDAQ:INMD), a leading provider of innovative aesthetic medical technologies, reported financial results for the fourth quarter and full year ended December 31, 2025.
CVS Health (NYSE:CVS) reported on Tuesday, February 10, 2026, that it has become the first pure-play healthcare company to surpass $400 billion in annual revenue, even as a series of heavy one-time charges masked the underlying strength of its Aetna and Caremark units.
Zimmer Biomet Holdings (NYSE:ZBH) reported fourth-quarter results on Tuesday, February 10, 2026, that exceeded Wall Street expectations, though the medical device giant’s shares remained under pressure following a "cautious" outlook for the coming fiscal year.
